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Abstract
Background: China has the second highest caseload of multidrug-resistant tuberculosis (MDR-TB) in the world.
In 2009, the Chinese government agreed to draw up a plan for MDR-TB prevention and control in the context of a
comprehensive health system reform launched in the same year.
Discussion: China is facing high prevalence rates of drug-resistant TB and MDR-TB. MDR-TB disproportionally affects
the poor rural population and the highest rates are in less developed regions largely due to interrupted and/or
inappropriate TB treatment. Most households with an affected member suffer a heavy financial burden because of a
combination of treatment and other related costs. The influential Global Fund programme for MDR-TB control in
China provides technical and financial support for MDR-TB diagnosis and treatment. However, this programme has
a fixed timeline and cannot provide a long term solution. In 2009, the Bill and Melinda Gates Foundation, in
cooperation with the National Health and Family Planning Commission of China, started to develop innovative
approaches to TB/MDR-TB management and case-based payment mechanisms for treatment, alongside increased
health insurance benefits for patients, in order to contain medical costs and reduce financial barriers to treatment.
Although these efforts appear to be in the right direction, they may not be sufficient unless (a) domestic sources
are mobilized to raise funding for TB/MDR-TB prevention and control and (b) appropriate incentives are given to
both health facilities and their care providers.
Summary: Along with the on-going Chinese health system reform, sustained government financing and social
health protection schemes will be critical to ensure universal access to appropriate TB treatment in order to reduce
risk of developing MDR-TB and systematic MDR-TB treatment and management.
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Background
After two decades of international efforts to combat
tuberculosis (TB), the global mortality rate (deaths per
100,000 population per year) has decreased by 45 %
since 1990 and incidence rates (new cases per 100,000
population per year) are also falling in most parts of the
world [1]. However, the increasing prevalence of drug-
resistant tuberculosis (DR-TB) is undermining global TB
control. In 2012, there were an estimated 450,000
patients suffering from multidrug-resistant tuberculosis
(MDR-TB) (defined as tuberculosis caused by strains of
Mycobacterium tuberculosis that are at least resistant to
rifampicin and isoniazid treatment), and an estimated
170,000 deaths from MDR-TB [1]. It was also estimated
that more than 75 % of those with MDR-TB were not di-
agnosed, the majority in countries with a high MDR-TB
burden [1]. This situation is generally ascribed to a com-
bination of insufficient laboratory facilities, a lack of ap-
propriately qualified health professionals and weak TB
surveillance systems. Globally, around 82 % of detected
MDR-TB patients in 2012 had started second-line treat-
ment. However, treatment coverage varied notably by
geographical area, with only 51 % of MDR-TB patients
under treatment in the World Health Organization
(WHO) African Region in that year [1]. Undetected
MDR-TB cases and treatment coverage gaps have been
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highlighted as constituting a global public health crisis
in the 2013 Global TB Report.
The WHO recommends a TB control strategy that in-
cludes government commitment, early diagnosis by bac-
teriologic testing, standardized treatment and regular
patient management. This DOTS (directly observed
treatment, short-course) strategy [2] has made notable
progress in global TB control, saving an estimated 6
million lives between 1995 and 2008 [3]. In 2005, the Stop
TB Partnership launched a new strategy for 2006–2015,
which specified financing and management interventions
for both drug-susceptible and drug-resistant TB control.
However, it has been argued that both funding and imple-
mentation have lagged far behind the action plan targets,
and that political commitment on MDR-TB prevention
and control is insufficient [4]. In 2009, WHO, the Bill
and Melinda Gates Foundation and the Chinese Ministry
of Health (now called the National Health and Family
Planning Commission of China, NHFPC) organized a
ministerial meeting in Beijing calling for action to tackle
TB and DR-TB in 27 countries with a high burden of
MDR-TB and extensively drug-resistant tuberculosis
(XDR-TB) [5]. In the meeting, China reported a serious
MDR-TB epidemic and agreed to draw up a plan for
MDR-TB prevention and control in the context of a com-
prehensive health system reform launched in the same
year.
The new round of health system reforms in China has
emphasized the role of government in funding and
supervision, and aims to achieving equitable and afford-
able access to quality health care for all. Over 2009–
2011, the Chinese government committed to invest CNY
850 billion (US$ 125 billion) and set five key reform pri-
orities: 1) speeding up the establishment of three basic
health insurance schemes (the rural New Cooperative
Medical Scheme (NCMS), the Urban Residence Basic
Medical Insurance (URBMI), and the Urban Employee
Basic Medical Insurance (UEBMI)) and medical financial
assistance for the poor; 2) developing a national system
to ensure the availability and affordability of quality essen-
tial medicines for all; 3) strengthening primary health care
facilities, particularly in the rural areas and urban commu-
nity settings to ensure the provision of cost-effective care;
4) promoting and improving equity in public health
services; 5) exploring public hospital reform through
pilot studies [6]. The achievements over these three
years are impressive, including universal health insurance
coverage, improved infrastructure of primary health
facilities and increased uptake of services [7].
The reform has recently entered a second phase to
tackle remaining challenges. The new four-year plan
(2012–2015) focuses on unifying China’s three health in-
surance schemes and increasing benefits, encouraging
payment reform to avoid perverse financial incentives to
healthcare providers, introducing performance-based fund-
ing for providers, expanding community and public health
services, and regulating drug production, prescription and
pricing [8]. The government commitment to health system
reform remains strong and the process is followed keenly
by national and international stakeholders.
To tackle TB, and particularly the MDR-TB epidemic,
strengthening the health system is critical. This paper
reviews the burden of MDR-TB and factors driving
MDR-TB in China, and then discusses the development of
MDR-TB prevention and control in line with the on-going
Chinese health system reform with a focus on financing
for TB/MDR-TB care.
Discussion
China has the second highest caseload of MDR-TB in
the world [1]. According to the National Survey of
Drug-Resistant TB in 2007, one third of new TB cases
and one half of previously treated cases exhibited anti-
TB drug resistance. Some 5.7 % (range 4.6–7.1 %) of
new cases and 25.6 % (range 21.7–30.0 %) of previously
treated cases developed MDR-TB [9]. The results of this
survey confirmed an estimate of around 100,000 emer-
ging MDR-TB cases annually in China. Among MDR-TB
patients, 7.2 % (range 4.9–10.2 %) were diagnosed as
XDR-TB, around 8,200 cases [9]. In addition, 11 % of
new cases and 16 % of previously treated cases were re-
sistant to either isoniazid or rifampicin and were at high
risk of developing MDR-TB [10]. Likewise, one third of
patients with MDR-TB had drug resistance to either
ofloxacin or kanamycin [10] and were one step away
from XDR-TB. These findings have sounded an alarm
that the prevalence of MDR-TB and XDR-TB in China
could easily increase.
Although knowledge gaps as to the causes of MDR-TB
remain, interrupted and/or inappropriate TB treatments
have been identified as the most important contributory
factors in China [10–12]. It has been argued that they
can be at least partially attributed to health system fail-
ures, in particular the reliance on a fee-for-services ap-
proach to financing public health facilities. TB has been
seen as a disease of the poor. It is not surprising that the
risk of developing MDR-TB is highest for poor and/or
vulnerable members of the population. Most cases are
found in the less developed northeast and southwest re-
gions [13]. Some 80 % of MDR-TB patients are from
rural areas, and most had low education and were in the
young to middle age-groups [14].
In the 1990s, the national TB control programme re-
quired the prompt referral of TB suspects who had a
cough for more than three weeks, hemoptysis or blood
in a sputum sample to TB dispensaries for diagnosis,
and provided free first-line anti-TB drugs for diagnosed
patients. This was seen as essential in order to remove,
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or at least substantially decrease, financial barriers to
accessing standard TB care by the poor. However, ac-
cording to an evaluation of China TB control in 2004–
2005, 70 % of suspects were not referred to TB dispens-
aries for diagnosis [15] but treated as non-TB cases in
public hospitals. Most patients spent more than half of
their annual income on treatment before being diag-
nosed with TB [16]. In addition, many studies in China
have reported that TB patients are charged for longer
treatment periods than recommended by the TB control
programme and that drugs and tests are administered to
an extent considerably beyond that specified in the
standard treatment regimen [17, 18]. As a result, many
patients have paid excessive fees for TB treatment or
have dropped out and/or discontinued treatment be-
cause of difficulties in affording care [19]. In addition, a
lack of proper training has often resulted in irrational
prescriptions and treatments [12].
Treatment of MDR-TB is complicated, expensive and
often unsuccessful, resulting in a low cure rate, high
mortality rate and low follow-up rate [20]. The WHO
guidelines for MDR-TB recommend 18–24 months of
chemotherapy using a combination of first- and second-
line drugs (including daily injections in the first 6–8
months). One systematic review that identified four
studies on the cost of MDR-TB treatment found that the
cost per case was substantially higher in two locations
where routine care included substantial hospitalization
(US$ 14,657 in Tomsk and US$ 10,880 in Estonia) than
where it only involved ambulatory care (US$ 3,613 in
the Philippines and US$ 2,423 in Peru) [21]. One study
in China reported average daily medical costs for MDR-
TB treatment were more than three times the average
cost of household daily non-food consumption in Tianjin
city and one and a half times in Henan province [22].
Some 92 % of MDR-TB patients in Tianjin and 70 % of
patients in Henan experienced catastrophic healthcare
payments (defined in this study as daily medical costs be-
ing over 40 % of daily non-food consumption) [22].
Progress on MDR-TB control in China
Drug-resistant TB prevention and control, especially
with regards to MDR-TB, has been an important compo-
nent of the national TB control programme in China
[19]. Since the 1990s, China has adopted the DOTS
strategy for systematic management of TB cases, imple-
mented in a semi-vertical TB control system affiliated
with the Center for Disease Control and Prevention
(CDC) at four levels: national, provincial, prefectural,
and county/district. National and provincial TB preven-
tion and control centers were usually responsible for
programme administration, TB care supervision and case
reporting. Lower level TB dispensaries focused on the
diagnosis of TB suspects, treatment and management. TB
patients with complications were referred to public hospi-
tals. In 1998, with the increasing prevalence of MDR-TB
and other TB related diseases (e.g., TB/HIV, TB/diabetes
co-infections etc.), pilot exercises to integrate TB care into
public hospitals was undertaken in Shanghai, Jiangsu and
Zhejiang provinces and a few sites in the less developed
western areas. TB clinics were set up within public hospi-
tals to provide TB/MDR-TB diagnosis and treatment and
to cooperate with the local TB dispensary on case man-
agement and reporting. This so called ‘designated hospital
model’ for TB control [23] is now being scaled up.
The central government provided annual earmarked
funding to cover the costs of first-line anti-TB drugs,
two X-ray examinations and five sputum smear tests for
TB, but there was no designated fund for MDR-TB diag-
nosis and treatment at the national level [24]. Several
international donors supported targeted interventions
on MDR-TB prevention and control in China, which
were often project/programme based. For example, over
2010–2014 the Global Fund supported a programme on
strengthening MDR-TB management that was imple-
mented in 89 prefectures of 30 provinces [25]. The main
contents of this programme included: drug susceptibility
testing (DST) with smear-positive patients; DR-TB surveil-
lance in project sites; the introduction of rapid MDR-TB
diagnosis technology; covering the cost of hospital admis-
sion for MDR-TB treatment; providing MDR-TB patients
with a transport subsidy; improving the quality of second-
line drugs produced in China; and ensuring a consistent
supply of second-line drugs. Matching funds from both
provincial and prefecture levels were required to co-
financing the programme [25]. In the project sites of the
Global Fund, 62 % of registered TB cases were tested for
drug susceptibility in 2010. The ratio of MDR-TB cases di-
agnosed to enrolments on MDR-TB treatment was 57 %
and over two thirds of MDR-TB patient sputum culture
examinations were negative by the end of 6-months of
treatment, which was much higher than in non-project
sites [26]. However, the Global Fund programme is time-
limited and sustainable long-term interventions need to
be established.
China’s ongoing health system reform towards univer-
sal healthcare coverage provides important opportunities
to improve access to appropriate care to prevent, diag-
nose and treat TB/MDR-TB and protect patients from
financial hardship. In 2009, a comprehensive programme
that aims to improve MDR-TB diagnosis and the quality
and affordability of treatment was developed and imple-
mented in four cities, supported by the Government of
China and the Melinda and Bill Gates Foundation. The
strategies included: the introduction of rapid molecular
diagnosis for isoniazid and rifampicin susceptibility
and associated laboratory staff training; standardized
and detailed MDR-TB treatment protocols based on
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the estimated degree of drug resistance; the use of health
insurance and other funds to cover 90 % of the medical
costs of MDR-TB diagnosis and treatment and to
subsidize transport and nutritional supplementation; and
strengthening MDR-TB patient management using a TB
control network, particularly in primary care facilities and
the community. The effects of the programme have been
impressive, with a substantial increase in the number of
diagnosed patients and use of appropriate treatment.
There has also been a significant decrease in the average
ratio of out-of-pocket payment to annual household
income [27].
In 2012 China CDC and the Foundation initiated
Phase II of the programme. In addition to confirmed ef-
fective diagnosis, treatment and patient management ap-
proaches, this emphasizes a sustainable financing
mechanism for TB/MDR-TB treatment. It was proposed
that health insurance schemes (NCMS, URBMI and
UEBMI) should cover both inpatient and outpatient TB
care and that the reimbursement rate should be in-
creased to 80 % for TB treatment and 90 % for MDR-TB
treatment. This was intended to reduce the financial
burden on TB/MDR-TB patients and improve patient
adherence to treatment. A case-based payment mechan-
ism for TB/MDR-TB treatment was designed to ensure
cost containment and standardized clinical practice. In
addition, the provision of a transport subsidy for TB/
MDR-TB patients was explored through cooperation
with the Civil Affairs Bureau which is in charge of the
Medical Financial Assistance scheme. The strategies for
MDR-TB control in this programme are shown in
Table 1. Health financing and payment reform is a critical
component of the overall Chinese health system reforms.
Good practice and lessons drawn from this ongoing TB
control programme will be valuable for the ongoing
development of health financing policy.
Challenges on MDR-TB control in China and the way forward
Efforts to combat TB/MDR-TB in China have made
substantial progress. However, critical weaknesses could
jeopardize effective implementation of the current strategy.
In this paper, we discuss challenges to TB/MDR-TB con-
trol in China from a health financing perspective.
Although government funding for TB/MDR-TB con-
trol has increased year by year, there remains a substan-
tial shortfall in terms of providing the financial support
needed to ensure effective TB/MDR-TB diagnosis, treat-
ment and management. Based on data from the national
population census in 2010, and the national TB and
MDR-TB surveys in 2010 and 2007 respectively, an esti-
mated CNY 13 million per annum is required for TB
control in each prefecture and CNY 4.6 million for
MDR-TB [28]. A survey carried out in three prefectures
in 2013 found that the annual funding allocated to TB
control was only one third of that required in two pre-
fectures in the eastern and central regions and much less
in the western prefecture [24]. Funding for MDR-TB
was far below the suggested level in all three prefectures,
and largely relied on the Global Fund, even in the de-
veloped eastern region [24]. When the Global Fund
programme for MDR-TB control ends, the funding
shortfall for MDR-TB will increase substantially if do-
mestic sources are not mobilized.
It is of great concern that the less developed regions
often have a higher burden of TB/MDR-TB but propor-
tionally much lower expenditure on prevention and con-
trol. This reflects the limited funds allocated to health
services in general, which can in turn be linked to their
overall poor fiscal status. With the decline in inter-
national donor funding, it has been proposed that low-
and middle-income countries, especially the emerging
economies (e.g., Brazil, Russia, India, China and South
Africa) should increase the amount they spend on com-
bating the MDR-TB epidemic as a means of ensuring
sustainable development. China’s economic success over
the reform period has generated the resources which
would allow a substantial increase in the funding of ini-
tiatives to address the MDR-TB public health crisis.
These initiatives will need to take into account regional
disparities in both the challenges faced by those con-
fronting TB/MDR-TB and the overall financial resources
available at the local level.
In China, MDR-TB diagnosis and treatment practices
vary by prefecture. In general, TB designated hospitals
and the CDC at city and/or higher levels are able to con-
duct DST and MDR-TB treatment. In some settings,
Table 1 Strategies for MDR-TB control in the China-Gates TB programme Phase II
Technical approach System strengthening Financing and payment
• MDR-TB detection: All smear or culture
positive patients are tested for drug
susceptibility using rapid molecular test
• Referral: County TB designated hospitals are required
to refer all MDR-TB patients (Rifampicin resistant inclusive)
to city TB designated hospital for diagnosis and treatment
• Health insurance benefits: The
reimbursement rate should be 90 %
for MDR-TB treatment
• MDR-TB treatment: All MDR-TB (Rifampicin
resistant inclusive) patients are treated with
standard second line TB regimen and tailed
regimen based on tested degree of drugs
resistance
• Patient management: 1) Staffs in local CDC and
primary health facilities are responsible for MDR-TB
patients management for 24 months; 2) MDR-TB
patients management information shared between
TB designated hospitals and CDCs without barriers
• Transportation subsidy for patients
through grant from local Civil Affairs
Bureau
• Case-based payment for the full
course of MDR-TB treatment
Data source: Baseline survey report of the comprehensive TB control model, China CDC, 2013
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county or district TB designated hospitals and/or the
CDC are responsible for delivering the samples from all
smear-positive patients and treatment failure patients to
city or higher level facilities for sputum culture examina-
tions and DST. In some settings, smear-positive and
treatment failure patients are recommended to visit city
or higher level facilities in person for DST.
According to the CDC TB register, the average delay
in 2013 between identification as an MDR-TB suspect
and an MDR-TB diagnosis ranged from 59 to 83 days in
the three prefectures in the eastern, central and western
regions identified above [24]. Interviews with the head of
the TB department in the local CDC, TB designated hos-
pital managers and TB care providers in each of the
three prefectures identified some common constraints
resulting in long delays in MDR-TB diagnosis. These
included lack of funds and/or incentives at county or
district TB facilities to ensure the correct and timely
delivery of patient samples, and the perception by pa-
tients, especially poor patients, that they would have
difficulty in affording care [24].
After diagnosis, it is recommended that all MDR-TB
patients should be admitted to a prefecture TB desig-
nated hospital for an initial 1–2 month period and then
should continue outpatient treatment for 16–18 months.
Treatment is individualized, being determined by the
specific drugs to which a patient exhibits resistance, and
the cost is some ten times that of standard TB treatment
[28]. Although most rural patients have NCMS coverage,
the reimbursement rate for hospital admission is usually
low (based on the NCMS principle of lower reimburse-
ment rates at higher level health facilities) and out-
patient costs are often not covered. A survey in three
prefectures located in the eastern, central and western
regions in 2013 reported that the average out-of-pocket
payment for MDR-TB treatment over a 24 month period
was CNY 20,544 [24]. Non-medical costs (including fees
for transport and accommodation during treatment)
were around one third of the medical cost. In this sur-
vey, almost all patients reported that the financial bur-
den on their households was heavy or very heavy and
half reported borrowing money from their relatives or a
bank to pay for treatment. These three prefectures were
all sites covered by the Global Fund programme, which
provided financial support for treatment and transport.
It may be inferred that MDR-TB treatment would be less
affordable in non-project sites and might give rise to
more serious economic and social consequences.
The China-Gates project Phase II introduced new finan-
cing and payment methods to reduce the financial barriers
to accessing MDR-TB treatment (including cooperation
with the Civil Affairs Bureau to subsidise patient travel
costs). However, it was recognized that without appropri-
ate incentives to both TB designated hospitals and their
TB care providers, there was a risk of undermining this
intervention. At the prefecture level, the revenues of TB
designated hospitals were still largely from service charges
[24]. In qualitative interviews with prefecture health ad-
ministrators, CDC directors and TB designated hospital
managers in the three prefectures, most expressed the
opinion that the implementation of case-based payments
for TB/MDR-TB treatment in prefecture TB designated
hospitals would lead to a decline in hospital revenues [24].
This would reduce the incentive to treat TB/MDR-TB and
might negatively impact the quantity and/or quality of
care provided. Another important consideration is that
the salaries of TB care providers in hospitals are directly
related to the associated service fees. Most TB care pro-
viders interviewed were not satisfied with their current
salaries, which were typically less than their colleagues in
other departments. There was also concern that they
might be exposed to a high occupational risk in treating
infectious diseases. This had made it difficult to recruit
TB doctors [24].
Financial and material incentives have been directed at
individual healthcare providers and organizations (both
public and private) in many other low- and middle-
income countries, aiming to improve the quality of TB
diagnosis and treatment, typically alongside system
changes intended to promote improved outcomes. For
example, in Romania and Honduras incentives (e.g., gift
tickets or other materials) were given to public healthcare
providers conditional on objective performance indicators,
for example the number of new cases confirmed by mi-
croscopy, the rate of DOT in sputum-positive patients,
and patient attendance for TB treatment [29]. In India,
the Philippines and Myanmar, private healthcare providers
were supplied free anti-TB drugs on condition that
patients did not pay for these [29, 30]. Dispensing
free drugs is seen as an incentive for private providers
because they can charge consultation fees and develop
their reputation for curing TB patients, which might
raise client demand for other services. There have also
been trials involving the provision of conditional financial
incentives at organization level (e.g., non-governmental
organizations, anti-TB teams, local governments) linked
to TB control performance indicators [29]. It is difficult to
fully attribute performance changes to these incentives
given that they were often just one component of multifa-
ceted interventions. However the evidence does seem to
indicate increased effectiveness in case detection and
treatment completion where incentives were offered to
providers and/or patients [29]. Findings from studies in a
number of countries emphasise the need for great care in
both the design of such incentives and their implementa-
tion, which requires a detailed understanding of the
environment within which providers operate and their
needs, as well as scientific evaluation of effectiveness.
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These international experiences should be considered
in the on-going reform of TB diagnosis and treatment
financing in China. Developing a hospital compensation
strategy that includes appropriate incentives for TB care
providers will be an essential component of an effective
intervention.
Summary
The high prevalence of drug-resistant TB, especially
MDR-TB and XDR-TB, is a global public health crisis. In
2009, the Beijing Call for Action and the World Health
Assembly Resolution 62.15 made clear that the actions
taken to address this crisis by national TB control pro-
grammes were insufficient. Radical policy changes were
required which would involve the strengthening of
health systems and services and increased government
accountability [31, 32].
The Chinese government commitment on combat-
ing TB/MDR-TB remains strong. In the context of a
new round of Chinese health system reforms, the Bill
and Melinda Gates Foundation in cooperation with
the government of China started to develop innova-
tive approaches to TB/MDR-TB prevention and con-
trol including 1) new MDR-TB diagnosis, treatment
and management mechanisms; 2) increased health in-
surance benefits and a travel subsidy provided by the
Civil Affair Bureau to remove financial barriers to ac-
cess to treatment; 3) a case-based payment method to
contain costs. Although these efforts appear to be in
the right direction, they may not be sufficient unless:
1) domestic sources are mobilized to raise funding for
TB/MDR-TB prevention and control; and 2) appropriate
incentives are given to both health facilities and their care
providers. Overall, the policies required to achieve these
objectives cannot be limited to the health sector but
will need cooperation across sectors including finance,
social welfare and labour. Findings from the on-going
China-Gates TB programme Phase II will require
careful analysis and interpretation in relation to the
effects of TB/MDR-TB control and financial protec-
tion for patients in order to guide evidence-based
policy development.
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